ClinicalTrials.gg
RecruitingNCT06399900ENLIGHTEN PADUpdated Apr 15, 2026

ENhancing Exercise With LIGHT to Improve Functioning in PAD

An interventional study of Far red light therapy and Sham light therapy in Peripheral Artery Disease, Peripheral Vascular Disease and Aging, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Northwestern University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Peripheral Arterial Disease by Northwestern University — 8 open to participants now, 10 under way, 4 of them phase 3. Peripheral Arterial Disease · Northwestern University.

Planned enrollment
21st of 24
32 · median 192
Started
2024
with 2 others
No phase
12 of 26
2 open now
Registered
23rd of 26
by date

Among the 26 studies in Peripheral Arterial Disease by Northwestern University, this one is the 21st largest by planned enrollment of the 24 interventional ones that give a count, is one of 3 that started in 2024, is one of 12 with no phase, and was the 23rd registered.

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

Browse Peripheral Arterial Disease studies →

Open to participants now

8 of the 26 studies in Peripheral Arterial Disease by Northwestern University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Peripheral Arterial Disease by Northwestern University, or all of them as a file.
02

Study summary

The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD).

Read the detailed description

The ENLIGHTEN PAD Trial will collect preliminary data to test whether daily 660 nm light treatment of the lower extremities immediately before home-based walking exercise sessions improves six-minute walk distance at 4-month follow-up, compared to sham light, in people with lower extremity peripheral artery disease (PAD) (Primary Aim #1). In Primary Aim #2, the investigators will measure the acute effect of the first treatment of 660 nm light on six-minute walk distance and on walking intensity (measured with the ActiGraph accelerometer) during the six-minute walk. In secondary and exploratory aims, the investigators will delineate biologic pathways by which 660 nm light enhances the benefits of home-based walking exercise, by measuring the effects of 660 nm light on exercise intensity during the exercise intervention and by measuring the effects of 660 nm light on plasma nitrosothiols, leg perfusion, and gastrocnemius muscle health and mitochondrial activity. Exercise intensity will be measured by the well validated ActiGraph accelerometer.

The ENLIGHTEN PAD Trial is a Phase II multi-centered randomized clinical trial. Thirty-two participants with PAD will be randomized at one of two centers: Northwestern University (PI: MM McDermott, MD) and the University of Alabama (PI: Nicole Lohr MD, PhD) to either 660 nm light + home-based exercise or sham light + home-based exercise for four months. Both groups of participants will receive the same home-based high intensity walking exercise intervention.

03

Conditions studied

  • Peripheral Artery Disease
  • Peripheral Vascular Disease
  • Aging
  • Walking, Difficulty

Keywords

  • light therapy
  • peripheral artery disease
  • exercise
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

First, all participants will be age 50 and older. Second, all participants will have PAD. PAD will be defined as:

  1. An ABI \<= 0.90 at baseline.
  2. Vascular lab evidence of PAD (such as a toe brachial pressure \<= 0.70 or an ankle brachial index less than or equal to 0.90), or angiographic evidence of PAD defined as at least 70% stenosis of an artery supplying the lower extremities.
  3. An ABI of >0.90 and \<= 1.00 who experience a 20% or greater drop in ABI in either leg after the heel-rise test.

Exclusion criteria

Exclusion Criteria:

  1. Above- or below-knee amputation
  2. Critical limb ischemia defined as an ABI \<0.40 with symptoms of rest pain
  3. Wheelchair confinement or requiring a walker to ambulate
  4. Walking is limited by a symptom other than PAD
  5. Current foot ulcer on bottom of foot
  6. Failure to successfully complete the study run-in
  7. Planned major surgery, coronary or leg revascularization during the next four months
  8. Major surgery, coronary or leg revascularization or major cardiovascular event in the previous three months
  9. Major medical illness including lung disease requiring oxygen, Parkinson's disease, a life-threatening illness with less than six months, or cancer requiring treatment in the previous two years. [NOTE: potential participants may still qualify if they have had treatment for an early stage cancer in the past two years and the prognosis is excellent, unless the cancer is located in the lower extremities. Participants who require oxygen only at night may still qualify.]
  10. Mini-Mental Status Examination () score \< 23
  11. Non-English speaking
  12. Participation in or completion of a clinical trial in the previous three months. [NOTE: after completing a stem cell or gene therapy intervention, participants will become eligible after the final study follow-up visit of the stem cell or gene therapy study so long as at least six months have passed since the final intervention administration. After completing a supplement or drug therapy (other than stem cell or gene therapy), participants will be eligible after the final study follow-up visit as long as at least three months have passed since the final intervention of the trial.]
  13. Visual impairment that limits walking ability.
  14. Six-minute walk distance of \<400 feet or >1700 feet.
  15. Participation in a supervised treadmill exercise program or a cardiac rehabilitation program in previous three months or planning to begin a supervised treadmill exercise program or a cardiac rehabilitation program in the next five months.
  16. Unwilling to avoid red light therapy outside of study participation.
  17. Baseline blood pressure \<100/45.
  18. In addition to the above criteria, investigator discretion will be used to determine if the trial is unsafe or not a good fit for the potential participant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Far red light therapy + home-based walking exercise

    Subgroup of participants receiving home-based walking exercise and the 670 nm far red light device

    Device: Far red light therapy · Behavioral: Home-based walking exercise

  • Sham comparator
    Sham therapy + home-based walking exercise

    Subgroup of participants receiving home-based walking exercise and the sham light device, far red light device covered with blue filter paper to block 670 nm light, resulting in mean power generated of 0.24 mW/cm2, compared to 26.3 mW/cm2 for the intervention, a 100-fold difference.

    Device: Sham light therapy · Behavioral: Home-based walking exercise

Interventions

  • DeviceFar red light therapy

    All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.

  • DeviceSham light therapy

    All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.

  • BehavioralHome-based walking exercise

    This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.

06

What researchers measure

Primary outcomes

  1. Six-Minute Walk Distance

    Change in six-minute walk distance

    Time frame: Measured at baseline and 4-month follow-up

  2. Six-Minute Walk Distance

    Change in six-minute walk distance (acute effect)

    Time frame: Measured immediately after the first light treatment (within 15 minutes after the first treatment, acute effect)

Secondary outcomes

  1. Six-Minute Walk Distance

    Change in six-minute walk distance (chronic effect)

    Time frame: Measured at 4-month follow-up, 24 hours after the final treatment

  2. Gastrocnemius Perfusion

    Changes in calf perfusion at 3 Tesla measured with arterial spin labeling with MRI and post-cuff occlusion hyperemia

    Time frame: Measured at baseline and 4-month follow-up

  3. Minutes of High Intensity Exercise

    Change in minutes of high intensity exercise/week (measured by the ActiGraph activity monitor)

    Time frame: Measured at baseline and 4-month follow-up

  4. Mean Exercise Intensity

    Change in mean exercise intensity (measured by the ActiGraph activity monitor)

    Time frame: Measured at baseline and 4-month follow-up

  5. Mean Exercise Intensity During Six-Minute Walk

    Change in mean exercise intensity during the six-minute walk (measured by the ActiGraph activity monitor)

    Time frame: Measured at baseline and 4-month follow-up

  6. Walking Impairment Questionnaire Distance Score

    Participant report of difficulty walking increasingly longer distances. Score range 0-100, 100 is best

    Time frame: Measured at baseline and 4-month follow-up

  7. PROMIS Mobility Score

    PROMIS mobility score from administered PROMIS questionnaire. Score range is from zero to infinity and a higher score means a better outcome.

    Time frame: Measured at baseline and 4-month follow-up

Other outcomes

  1. Walking Impairment Questionnaire Speed Score

    Participant report of ability to walking increasing number of stair flights (0-100 score, 100-best)

    Time frame: Measured at baseline and 4-month follow-up

  2. Walking Impairment Questionnaire Stair Climbing Score

    Participant report of ability to walking increasing number of stair flights (0-100 score, 100-best)

    Time frame: Measured at baseline and 4-month follow-up

  3. Short-Form 36 (SF-36) Score (0-100 score, 100-best)

    Change in score on the SF-36 from baseline to follow-up

    Time frame: Measured at baseline and 4-month follow-up

  4. Short Physical Performance Battery (SPPB)

    SPPB range, range 0-12, 12-best

    Time frame: Measured at baseline and 4-month follow-up

  5. Plasma Nitrite

    Changes in plasma abundance of nitrite

    Time frame: Measured before and within five minutes after the first light treatment at baseline

  6. Plasma Nitrite

    Changes in plasma abundance of nitrite

    Time frame: Measured before and within five minutes after the final light treatment at 4-month follow-up

  7. Plasma Nitrosothiols

    Changes in plasma abundance of nitrosothiols

    Time frame: Measured before and within five minutes after the first light treatment at baseline

  8. Plasma Nitrosothiols

    Changes in plasma abundance of nitrosothiols

    Time frame: Measured before and within five minutes after the final light treatment at 4-month follow-up

  9. Gastrocnemius Muscle Capillary Density

    Changes in gastrocnemius muscle capillary density

    Time frame: Measured at baseline and 4-month follow-up

  10. Gastrocnemius Muscle Myofiber Size

    Changes in gastrocnemius muscle myofiber size

    Time frame: Measured at baseline and 4-month follow-up

  11. Gastrocnemius Muscle Citrate Synthase Activity

    Changes in gastrocnemius muscle citrate synthase activity

    Time frame: Measured at baseline and 4-month follow-up

  12. Gastrocnemius Muscle Cytochrome C Oxidase Activity

    Changes in gastrocnemius muscle cytochrome c oxidase activity

    Time frame: Measured at baseline and 4-month follow-up

  13. Gastrocnemius Muscle Abundance of Satellite Cells

    Changes in gastrocnemius muscle abundance of satellite cells

    Time frame: Measured at baseline and 4-month follow-up

  14. Gastrocnemius Muscle Abundance of Myofibers with Central Nuclei

    Changes in gastrocnemius muscle abundance of myofibers with central nuclei

    Time frame: Measured at baseline and 4-month follow-up

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2026, 25 months after the start.

Of 261 non-industry interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 64. This study's planned 25 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 6, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Jan 31, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06399900
Responsible party
Mary McDermott (Jeremiah Stamler Professor of Medicine, Northwestern University) — Principal investigator
First posted
May 6, 2024
Start date
Aug 12, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Mary McDermott, MD
Contact
mdm608@northwestern.edu
13125036419
Kathryn Domanchuk
Contact
kdomanchuk@northwestern.edu
312-503-6438

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion